研报 | 新加坡医疗保健每月快讯:公共医疗仍然处于领先地位

wechat omage

 

2018年11月,新加坡的医院入住率同比增长4.3%,其中公共部门所占的份额更大。
2018年9月,新加坡的出生率同比下降4.9%,这已是出生率第四个月缩减了。
2018年,新加坡年满65岁及以上的公民人数同比增长6.0%,与2017年同比增长的6.0% 持平。
马来西亚的B40 健康保险基金计划将为占人口40%的最底收入人群提供保险保障。

对新加坡的医疗保健部门维持中性评级。

 

新加坡

11月新加坡的医院住院率同比增长4.3%

11月份,公共部门的住院人数增长更快,同比增长5.6%,而私营部门的入院人数增长持平在0.1%。新加坡人正从私人医疗服务转向公共医疗服务,与住院医疗相比,他们更倾向选择门诊治疗。未来五年内,来自新建和即将落成的公立医院的竞争包括:Sengkang 综合社区医院,Outram 社区医院,综合护理中心,和Woodlands 综合医院将新增3,200 个急症病床以及1,050 社区医院病床。

2017年,新加坡的医生人数同比增长3.2%

从2008年到2017年间,新加坡的医生数量以6.1%的年复合增长率增长,使每万人拥有医生的数量从2008年的16人增加到2017年的24人。2017年,每万人拥有牙医的数量相对持平在4人,而对比2008年则为3人。

新加坡的医疗旅游笼罩在逆风之中

新加坡继续面临来自马来西亚和印尼等地区竞争对手,日益增强的医疗能力的更激烈竞争,再加上成本的上涨 (住宿和交通) 以及新元的走强等因素。对外国患者来讲,新加坡的医疗旅游变得不那么实惠,并且吸引力也越来越小了。许多医疗保健公司正在向海外扩张,比如莱佛士医疗集团即将在重庆落成的医院。酝酿成本最初可能会使盈利增长放缓,但良好执行的海外扩张可能会为长期的盈利增长带来有意义的上升空间。

 

马来西亚
B40 健康保障基金 (简称B40HPF)

马来西亚2019年预算宣布B40HPF (自2019年1月1日起生效),由联邦政府与私营保险行业合作试点,为占人口40%的最底收入人群提供保险保障;涵盖 (i) 36 种主要危重疾病,(ii) 最多14 天的住院收入,按每天50令吉或者每年700令吉计算。该计划将由马来西亚国家银行(BNM)管理。

此前,马来西亚的私营医疗保健部门主要由中上阶层至富裕阶层使用。随着针对马来西亚人口中占40%的最底收入人群的B40HPF 推出,我们相信该计划将使私营医疗保健公司受益,使更多的病人流向私营医疗部门,尽管是以折价方式进入。

 

投资行动
由于近期的逆风,我们对新加坡医疗保健行业维持中性评级。为了重新获得竞争优势,新加坡的私营医疗保健行业将必须专注于专业治疗上,消除定价意外,并利用海外扩张和并购。然而,高标准的医疗服务质量,严格的医疗法规以及日益增加的区域多元化,应有助于医疗保健行业克服这些短期的不利因素。

本文为英文翻译版本,仅供参考,一切请以英文版本为准。如果有想了解更多全球股市资讯,请关注微信公众共 “辉立资本新加坡” (SGPSPL)。同时提供在线免费开设股票账户,一个账户轻松交易美股,港股,新加坡股

关键字:新加坡股票研报,新加坡股,新加坡研报,新加坡账户,交易新加坡股票,新加坡股票开户,免费开户,在线开设新加坡股票开户,新加坡证券,新加坡券商,投资组合

联系我们开设账户

需要帮助吗?请分享您的详细资料,我们会给您答复。

IMPORTANT INFORMATION

This material is provided by Phillip Capital Management (S) Ltd (“PCM”) for general information only and does not constitute a recommendation, an offer to sell, or a solicitation of any offer to invest in any of the exchange-traded fund (“ETF”) or the unit trust (“Products”) mentioned herein. It does not have any regard to your specific investment objectives, financial situation and any of your particular needs. You should read the Prospectus and the accompanying Product Highlights Sheet (“PHS”) for key features, key risks and other important information of the Products and obtain advice from a financial adviser (“FA“) pursuant to a separate engagement before making a commitment to invest in the Products. In the event that you choose not to obtain advice from a FA, you should assess whether the Products are suitable for you before proceeding to invest. A copy of the Prospectus and PHS are available from PCM, any of its Participating Dealers (“PDs“) for the ETF, or any of its authorised distributors for the unit trust managed by PCM.  

An ETF is not like a typical unit trust as the units of the ETF (the “Units“) are to be listed and traded like any share on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Listing on the SGX-ST does not guarantee a liquid market for the Units which may be traded at prices above or below its NAV or may be suspended or delisted. Investors may buy or sell the Units on SGX-ST when it is listed. Investors cannot create or redeem Units directly with PCM and have no rights to request PCM to redeem or purchase their Units. Creation and redemption of Units are through PDs if investors are clients of the PDs, who have no obligation to agree to create or redeem Units on behalf of any investor and may impose terms and conditions in connection with such creation or redemption orders. Please refer to the Prospectus of the ETF for more details.  

Investments are subject to investment risks including the possible loss of the principal amount invested. The purchase of a unit in a fund is not the same as placing your money on deposit with a bank or deposit-taking company. There is no guarantee as to the amount of capital invested or return received. The value of the units and the income accruing to the units may fall or rise. Past performance is not necessarily indicative of the future or likely performance of the Products. There can be no assurance that investment objectives will be achieved.  

Where applicable, fund(s) may invest in financial derivatives and/or participate in securities lending and repurchase transactions for the purpose of hedging and/or efficient portfolio management, subject to the relevant regulatory requirements. PCM reserves the discretion to determine if currency exposure should be hedged actively, passively or not at all, in the best interest of the Products.  

The regular dividend distributions, out of either income and/or capital, are not guaranteed and subject to PCM’s discretion. Past payout yields and payments do not represent future payout yields and payments. Such dividend distributions will reduce the available capital for reinvestment and may result in an immediate decrease in the net asset value (“NAV”) of the Products. Please refer to <www.phillipfunds.com> for more information in relation to the dividend distributions.  

The information provided herein may be obtained or compiled from public and/or third party sources that PCM has no reason to believe are unreliable. Any opinion or view herein is an expression of belief of the individual author or the indicated source (as applicable) only. PCM makes no representation or warranty that such information is accurate, complete, verified or should be relied upon as such. The information does not constitute, and should not be used as a substitute for tax, legal or investment advice.  

The information herein are not for any person in any jurisdiction or country where such distribution or availability for use would contravene any applicable law or regulation or would subject PCM to any registration or licensing requirement in such jurisdiction or country. The Products is not offered to U.S. Persons. PhillipCapital Group of Companies, including PCM, their affiliates and/or their officers, directors and/or employees may own or have positions in the Products. Any member of the PhillipCapital Group of Companies may have acted upon or used the information, analyses and opinions herein before they have been published. 

This advertisement has not been reviewed by the Monetary Authority of Singapore.  

 

Phillip Capital Management (S) Ltd (Co. Reg. No. 199905233W)  
250 North Bridge Road #06-00, Raffles City Tower ,Singapore 179101 
Tel: (65) 6230 8133 Fax: (65) 65383066 www.phillipfunds.com